Key recent performance and what it might mean for investors
Revolution Medicines (RVMD) shares have seen mixed recent returns, with a 1 day decline of 0.75%, a 3.4% drop over the past week, and a roughly 9.3% decline over the past month.
Over the past 3 months, however, the stock shows a gain of about 14.9%, and year to date it is up roughly 17.1%. This provides investors with a sense of how sentiment has shifted across different time frames.
See our latest analysis for Revolution Medicines.
At a share price of US$92.51, Revolution Medicines has seen recent share price momentum cool over the past month. However, its 90 day gain and very large 1 year total shareholder return suggest investors have already reacted strongly to earlier progress and shifting expectations around its oncology pipeline and risk profile.
If you are comparing Revolution Medicines with other high growth healthcare names, it can help to scan a curated list of 34 healthcare AI stocks
With Revolution Medicines trading at US$92.51 and sitting at a very large discount to some valuation estimates, the key question is clear: is the stock still undervalued, or is the market already pricing in future growth?
Most Popular Narrative: 30% Overvalued
The latest widely followed narrative puts Revolution Medicines' fair value at $92.22, very close to the last close of $92.51. This frames the stock as slightly above that estimate despite a very large discount to some other valuation models.
Although the company has access to substantial liquidity with US$2.03b in cash and investments and up to US$1.75b of remaining committed capital from Royalty Pharma, GAAP operating expenses guided to US$1.6b to US$1.7b for 2026 signal heavy ongoing spend. This may delay any move toward positive earnings.
Curious how a company with no current revenue, large losses and ambitious margin assumptions still supports this fair value? The narrative leans on aggressive revenue expansion, changing profitability and a stretched future earnings multiple that looks very different from typical biotech benchmarks. The full story sits in how those pieces are combined and discounted.
Result: Fair Value of $92.22 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, a breakthrough approval from one of the eight registrational trials or effective use of the US$2.03b cash plus US$1.75b Royalty Pharma funding could quickly challenge that cautious view.
Find out about the key risks to this Revolution Medicines narrative.
Another View: Cash Flows Point to Deep Discount
That bearish fair value of $92.22 sits very close to the current $92.51 share price, yet the SWS DCF model paints a very different picture, with an estimate of future cash flow value at $520.71 per share and RVMD trading at an 82.2% discount. How much weight do you place on cash flows versus analyst sentiment?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revolution Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 62 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
The push and pull between risks and rewards in this story is clear, so consider acting promptly, review the numbers yourself and weigh up the 2 key rewards and 2 important warning signs
Looking for more investment ideas?
If you stop at one stock, you risk missing other opportunities that match your style, so take a few minutes to scan the market more broadly today.
- Expand your hunt for mispriced opportunities by checking a hand picked set of 62 high quality undervalued stocks that combine quality with attractive price tags.
- Strengthen the defensive side of your portfolio by reviewing a focused group of 64 resilient stocks with low risk scores that aim to keep volatility in check.
- Get ahead of the crowd by scanning a screener containing 25 high quality undiscovered gems that many investors may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com